Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RNXT
RNXT logo

RNXT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy RenovoRx Inc (RNXT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.930
1 Day change
-2.11%
52 Week Range
1.450
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RNXT is not a good buy right now for a beginner long-term investor with $50,000-$100,000. The stock is trading near short-term pivot resistance with no strong proprietary buy signal, no recent news catalyst, neutral insider/hedge fund activity, and no clear financial snapshot to support conviction. If you are unwilling to wait for a better entry, this is not an attractive immediate purchase.

Technical Analysis

RNXT is showing a weak-to-neutral setup. The price closed at 0.93, slightly above the previous close of 0.9201, but the broader market move and the stock's regular-session change indicate weak momentum. MACD histogram is slightly positive at 0.0048 but contracting, which suggests fading upside momentum. RSI_6 at 44 is neutral and does not indicate oversold conditions. Moving averages are converging, showing consolidation rather than a strong trend. Price is sitting just below the pivot level of 0.938, with resistance at 0.986 and 1.016, and support at 0.889 and 0.86. Overall, the chart is range-bound and lacks a clear bullish breakout signal.

Positive Catalysts

  • No news in the recent week. AI Stock Picker shows no signal on given stock today, and SwingMax shows no signal on given stock recently. There are no recent congress purchases or notable insider buying trends. The only mild positive is that MACD remains above zero, which suggests some underlying stability, but it is not strong enough to count as a catalyst.

Neutral/Negative Catalysts

  • No recent news-driven catalyst. Hedge funds are neutral and insiders are neutral, so there is no strong institutional or insider support. The stock is trading below the first resistance zone and is not demonstrating strong momentum. The proprietary trading signals are absent, and the candlestick-based trend model points to limited near-term upside with a negative one-month expectation.

Financial Performance

The latest quarter financials were not available due to a data error, so there is no reliable recent-quarter revenue or growth assessment to support a buy decision. Because the financial snapshot is missing, there is insufficient evidence of strong fundamental acceleration or improving growth trends from the latest quarter season.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no visible trend in Wall Street estimates. Based on the available information, Wall Street sentiment appears mixed to cautious: there are no bullish revisions, no notable target increases, and no clear pros-side catalyst. The cons side dominates because momentum is weak, signals are absent, and there is no supportive news or insider buying.

Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
Wall Street analysts forecast RNXT stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.948
sliders
Low
3
Averages
5.63
High
12.5
Current: 0.948
sliders
Low
3
Averages
5.63
High
12.5
JonesResearch
Justin Walsh
initiated
$8
AI Analysis
2026-01-29
Reason
JonesResearch
Justin Walsh
Price Target
$8
AI Analysis
2026-01-29
initiated
Reason
JonesResearch analyst Justin Walsh initiated coverage of RenovoRx with a Buy rating and $8 price target. RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being "particularly useful" for treating pancreatic cancer.
Alliance Global
Buy
maintain
$3
2025-11-14
Reason
Alliance Global
Price Target
$3
2025-11-14
maintain
Buy
Reason
Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RNXT
Unlock Now

People Also Watch